Feb 7 (Reuters) - Hims & Hers said in a

statement on Saturday that it will stop offering access to ‌the

compounded semaglutide pill after the U.S. Food and ​Drug

Administration said it would take action against ‍the telehealth

provider for its $49 weight-loss ⁠pill.

"Since launching ⁠the compounded semaglutide pill on our

platform, we've had ‌constructive conversations with stakeholders

across ​the industry. As a result, we have decided to stop

offering access ⁠to this treatment," ‍the company ​said.

The FDA

said

on Friday that it plans to restrict GLP-1 ingredients used

in non-approved compounded ‍drugs that companies such as Hims and

other compounding pharmacies have marketed as alternatives to

authorized treatments, citing concerns over quality, safety and

potential violations of federal law.

The ​FDA ‍said it would refer the company to the

Department of Justice but did ​not make clear whether it could

quickly halt the sale of the Hims' product, the cheapest GLP-1

therapy on the U.S. market.

Reuters

reported

on Thursday that Hims would begin offering copies of Novo

Nordisk's ​new Wegovy pill at an introductory price of

$49 per month, about $100 less than the brand name.